Table 4:
Ratios of the prevalence of medication use across categories of drinking status, sociodemographic characteristics, and over time.
Model 1: Opioid RR (95% CI) | Model 2: Sedative-Hypnoticsa RR (95% CI) | Model 3: Anxiolytics RR (95% CI) | Model 4: Sleep Medications RR (95% CI) | |
---|---|---|---|---|
Regular Drinking (vs. Infrequent drinking/abstinence) | 0.69 (0.60, 0.78) | 0.79 (0.70, 0.89) | 0.71 (0.61, 0.81) | 1.04 (0.80, 1.35) |
Sex (vs. Male) | ||||
Female | 0.86 (0.79, 0.94) | 0.67 (0.60, 0.74) | 0.62 (0.56, 0.70) | 0.79 (0.62, 0.99) |
Race (vs. White) | ||||
Black | 0.79 (0.69, 0.92) | 0.43 (0.37, 0.50) | 0.41 (0.34, 0.49) | 0.50 (0.38, 0.66) |
Hispanic | 0.48 (0.40, 0.57) | 0.45 (0.36, 0.55) | 0.44 (0.35, 0.56) | 0.46 (0.33, 0.64) |
Other | 0.72 (0.57, 0.91) | 0.63 (0.44, 0.90) | 0.56 (0.37, 0.84) | 0.72 (0.44, 1.19) |
Age (vs. 20-29) | ||||
30-39 | 1.36 (1.11, 1.67) | 1.76 (1.33, 2.32) | 1.64 (1.23, 2.19) | 2.96 (1.49, 5.85) |
40-49 | 1.79 (1.48, 2.17) | 2.64 (2.04, 3.40) | 2.31 (1.78, 3.00) | 5.57 (3.11, 9.97) |
50-64 | 1.89 (1.51, 2.35) | 3.22 (2.48, 4.19) | 2.93 (2.23, 3.86) | 5.93 (3.35, 10.51) |
65+ | 1.62 (1.33, 1.98) | 3.32 (2.61, 4.22) | 3.01 (2.33, 3.89) | 5.33 (2.89, 9.81) |
Educ. (vs. < HS) | ||||
HS Diploma | 0.81 (0.72, 0.92) | 0.94 (0.81, 1.08) | 0.94 (0.80, 1.11) | 0.89 (0.61, 1.28) |
>HS, no Degree | 0.76 (0.68, 0.86) | 0.91 (0.79, 1.05) | 0.87 (0.74, 1.03) | 1.15 (0.81, 1.63) |
College Degree+ | 0.41 (0.34, 0.49) | 0.64 (0.54, 0.77) | 0.54 (0.44, 0.65) | 1.13 (0.82, 1.56) |
Time (yr) | 1.03 (1.02, 1.05) | 1.04 (1.02, 1.06) | 1.03 (1.01, 1.05) | 1.09 (1.07, 1.12) |
The category of sedative-hypnotics is comprised of anxiolytics and sleep medications.
Notes: (1) relative risks (i.e. “RR”) calculated using log-binomial model; (2) all models contained all variables presented in the table; (3) regular drinking defined as consuming alcohol at least 52 times in the past year; (4) infrequent drinking/abstain defined as using alcohol less than 52 times in the past year; (5) opioid and sedative-hypnotic use defined as prescribed use of either medication for 30 days or longer.